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Table 1 – Characteristics of individual case reports 
AF=Atrial Fibrillation; CABG=Coronary Artery Bypass Graft; RA=Rheumatoid Arthritis; CA=Cancer;  CAD=Coronary Artery Disease; DVT=Deep Vein Thrombosis; IVDU=Intravenous Drug Use; 
CHF=Congestive Heart Failure; MI=Myocardial Infarction;  HTN=Hypertension; COPD=Chronic Obstructive Pulmonary Disease; TOF=Tetralogy of Fallot; HLD=Hyperlipidemia; 
TAVR=Transcatheter Aortic Valve Replacement; TMVR=Transcatheter Mitral Valve Replacement; ASA=Aspirin; TPA=Tissue Plasminogen Activator; VSD=Ventricular Septal Defect; Tx=Treatment
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Introduction
§ Direct oral anticoagulants (DOACs) are indicated to 
treat and prevent venous thromboembolism and to 
prevent stroke or systemic embolism in patients with 
non-valvular atrial fibrillation. 
§ The introduction of DOACs has provided an 
alternative to warfarin for patients in need of oral 
anticoagulation. It is, however, unclear whether 
DOACs are safe and effective in patients with heart 
valve replacement. 
§ The RE-ALIGN trial published in 2013 did not 
support the use of dabigatran in patients with 
mechanical valve replacements; however, there are 
ongoing studies, such as the PROACT Xa trial and 
the ATLANTIS trial, investigating the use of other 
DOACs in patients with heart valve replacements. 
§ This purpose of this study is to evaluate and describe 
a potential risk of thrombosis in patients with heart 
valve replacement and treated with a DOAC. 
Results 
§ Among 967 citations, 19 case reports involving 22 
patients were identified and assessed in this study. 
§ 45.5%, 31.8%, and 22.7% of the patients were taking 
dabigatran, rivaroxaban, and apixaban, respectively. 
§ 11 patients (50%) had mechanical valves, and 11 
patients (50%) had bioprosthetic valves. 
§ The average age of the patients was 65.2 years 
(SD±14.3) with 54.5% female. 59.1% of the patients 
had another indication for anticoagulation other than 
heart valve replacement. 
§ Of the patients with another indication for 
anticoagulation, 92.3% had atrial fibrillation, and 7.7% 
had deep vein thrombosis. 
§ 13.6% of the cases reported concurrent aspirin use 
§ 3 patients (13.6%) had cancer as a comorbid condition, 
and 1 patient (4.5%) had a valve-in-valve replacement. 
§ 95.5% of the 21 cases reported an intervention with 13 
patients (61.9%) receiving surgery (11 valve 
replacements, 2 thrombectomies) and 8 patients 
(38.1%) receiving medical management. 
§ 4.5% of the cases reported death prior to intervention. 
§ The time reported from onset of DOAC therapy to 
onset of thrombotic event ranged from 9 days to 33 
months. 
Summary of Case Reports
§ Following the PRISMA guidelines, a systematic 
literature search was performed on June 24th, 2020 
using three electronic databases (Pubmed, Embase, 
Cochrane Library) with the following key terms: 
(apixaban OR rivaroxaban OR edoxaban OR 
dabigatran OR direct oral anticoagulant OR factor 
Xa inhibitor OR direct thrombin inhibitor OR target 
specific oral anticoagulant) and (valve replacement 
OR valve implantation). 
§ Two authors independently screened the search 
result using Rayyan QCRI (a systematic review web 
app). Different decisions were resolved through 
consensus between the two authors with the input 
of the third author. 
FIGURE 1 – PRISMA flow diagram
§ All authors are affiliated with the Philadelphia College 





§ It is still uncertain whether DOACs are safe or effective 
in preventing valve thrombosis for different types of 
valve replacements. 
§ The use of DOACs in patients with valve replacement 
should be limited to those with no other alternative. 
§ Further research is needed to determine the 
effectiveness and safety of DOAC use in patients with 
prior valve replacements.
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